ReviewCurrent molecular medicine2008
Regulation of iron absorption in hemoglobinopathies.
Review in Current molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Serum ferritin in Yemeni patients with sickle cell anemia: Association with sociodemographic factors and hematological profiles.PloS one · 2026Article
- Hemoglobin to red cell distribution width ratio as a prognostic marker for ischemic stroke after mechanical thrombectomy.Frontiers in aging neuroscience · 2023Article
- Radiographic Features of the Maxillofacial Anomalies in Beta-Thalassemia Major: With New View.World journal of plastic surgery · 2021Article
- Correlation of hepcidin and serum ferritin levels in thalassemia patients at Chiang Mai University Hospital.Bioscience reports · 2021Article
- Red blood cell distribution width as long-term prognostic markers in patients with coronary artery disease undergoing percutaneous coronary intervention.Lipids in health and disease · 2019Article
- Hepcidin agonists as therapeutic tools.Blood · 2018Review
- What can we learn from ineffective erythropoiesis in thalassemia?Blood reviews · 2018Review
- Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major.Journal of clinical and experimental hepatology · 2017Article
- New strategies to target iron metabolism for the treatment of beta thalassemia.Annals of the New York Academy of Sciences · 2016Review
- Targeting Ion Channels: An Important Therapeutic Implication in Gastrointestinal Dysmotility in Patients With Spinal Cord Injury.Journal of neurogastroenterology and motility · 2015Article
- Tissue iron deficiency and adiposity-related inflammation in disadvantaged preschoolers from NE Brazil.European journal of clinical nutrition · 2014Article
- Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Uptake of non-transferrin iron by erythroid cells.Anemia · 2011Article
- Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.The Journal of clinical investigation · 2010Article
- Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.Hematology/oncology clinics of North America · 2010Review
- Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.Annals of the New York Academy of Sciences · 2010Article
- Future alternative therapies for β-thalassemia.Expert review of hematology · 2009Article
- Gene therapy in thalassemia and hemoglobinopathies.Mediterranean journal of hematology and infectious diseases · 2009Article
- Ineffective erythropoiesis and thalassemias.Current opinion in hematology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Beta-thalassemia and sickle cell anemia (SCD) represent the most common hemoglobinopathies caused, respectively, by deficient production or alteration of the beta chain of hemoglobin (Hb). Patients affected by the most severe form of thalassemia suffer from profound anemia that requires chronic blood transfusions and chelation therapies to prevent iron overload. However, patients affected by beta-thalassemia intermedia, a milder form of the disease that does not require chronic blood transfusions, eventually also show elevated body iron content due to increased gastrointestinal iron absorption. Even SCD patients might require blood transfusions and iron chelation to prevent deleterious and painful vaso-occlusive crises and complications due to iron overload. Although definitive cures are presently available, such as bone marrow transplantation (BMT), or are in development, such as correction of the disease through hematopoietic stem cell beta-globin gene transfer, they are potentially hazardous procedures or too experimental to provide consistently safe and predictive clinical outcomes. Therefore, studies that aim to better understand the pathophysiology of the hemoglobinopathies might provide further insight and new drugs to dramatically improve the understanding and current treatment of these diseases. This review will describe how recent discoveries on iron metabolism and erythropoiesis could lead to new therapeutic strategies and better clinical care of these diseases, thereby yielding a much better quality of life for the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.